Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc. Combined Company Renamed Vaxart, Inc. and Will Begin Trading Under New Symbol NASDAQ: VXRT SOUTH SAN FRANCISCO, CA and ATLANTA, Feb. 13, 2018 — Vaxart, Inc. (NASDAQ: VXRT) today announced the completion of its merger with Aviragen
CAS Group Supports Improved Deal Company Currently has Sufficient Votes to Approve Merger ATLANTA , Feb. 09, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced that the reconvened Special Meeting of Stockholders has been further adjourned to 10:00 AM, EST on February
Reiterates Transaction Represents Best Path Forward for Aviragen and ALL Stockholders CAS Group Has Not Articulated a Clear Plan and Has Now Changed its Stance to Emphasize Teslexivir (BTA074) ATLANTA , Jan. 31, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc.
Vaxart Merger is the Result of an Extensive Review of Strategic Alternatives and is in the Best Interest of ALL Stockholders Aviragen Board of Directors Unanimously Recommends that Stockholders Vote FOR the Proposed Merger with Vaxart ATLANTA , Jan. 26, 2018 (GLOBE NEWSWIRE) -- Aviragen
Reiterates Benefits of Proposed Merger with Vaxart Urges All Aviragen Stockholders to Vote FOR the Proposed Merger on the WHITE Proxy Card Today ATLANTA , Jan. 24, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today issued a letter to stockholders urging them to vote FOR
Transaction Creates a Leading Vaccine Company and Maximizes Value for Aviragen Stockholders Updated Investor Presentation Filed with Securities and Exchange Commission and Posted to Aviragen Website ATLANTA , Jan. 11, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc.
ATLANTA , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options, today announced the completion of patient enrollment in its Phase 2 CT4
ATLANTA , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three months ended September 30, 2017. "Earlier this week we were pleased to announce the culmination of our strategic review process with the signing of a definitive
Merged Company to Focus on Development of Antiviral Vaccines and Therapeutics Based on Proprietary Delivery Technology Platform Conference Call to be Held Today at 8:30 AM ET ATLANTA and SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc.